FIELD: pharmacology; medicine.
SUBSTANCE: group of inventions relates to the field of pharmacology and medicine; it is aimed at the treatment of bladder cancer. The use of a compound ABX196 having the formula (I) or one of its pharmaceutically acceptable salts in a method for the treatment of bladder cancer is disclosed, wherein the specified method does not include the administration of an additional chemotherapeutic agent and/or an immunotherapeutic agent, and/or an antigen. In addition, the use of a pharmaceutical composition including a compound ABX196 in a method for the treatment of bladder cancer is presented.
EFFECT: effective treatment of bladder cancer.
8 cl, 2 dwg, 4 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINATIONS FOR CANCER TREATMENT INCLUDING ABX196 | 2017 |
|
RU2770432C2 |
| COMBINATION OF TASQUINIMOD OR ITS PHARMACEUTICALLY ACCEPTABLE SALT AND PD-1 AND/OR PD-L1 INHIBITOR FOR USE AS A MEDICINAL AGENT | 2016 |
|
RU2742373C2 |
| MULTI-SPECIFIC ANTIBODIES INTENDED FOR USE IN TREATMENT OF URINARY TRACT NEOPLASM | 2017 |
|
RU2766358C2 |
| METHOD OF INHIBITING PD-1/PD-L1 SIGNALING PATHWAY IN BLADDER CANCER CELLS | 2023 |
|
RU2812805C1 |
| SINGLE-DOMAIN ANTIBODY AND DERIVATIVES THEREOF TO LIGAND-1 PROTEIN OF PROGRAMMED CELL DEATH (PDLI) | 2016 |
|
RU2715595C2 |
| COMBINED ANTICANCER THERAPY AND PHARMACEUTICAL COMPOSITIONS THEREFOR | 2005 |
|
RU2396960C2 |
| COMBINED TREATMENT METHODS USING ALK INHIBITORS | 2015 |
|
RU2718914C2 |
| METHODS OF TREATING CANCER USING ANTAGONISTS BINDING TO COMPONENTS OF THE SIGNAL PATH PD-1, AND TAXANES | 2014 |
|
RU2719487C2 |
| COMBINED IMMUNOTHERAPEUTIC APPROACH TO CANCER TREATMENT | 2015 |
|
RU2716821C2 |
| COMPOSITION FOR PREVENTING OR TREATING MALIGNANT TUMOUR, COMPRISING AGENT DESTROYING VESSELS, AND IMMUNE CONTROL POINT INHIBITOR | 2018 |
|
RU2738369C1 |
